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One of the 4 pillars of the World Health Organization (WHO) strategy for the prevention and
control of snake bite envenomings is to ensure safe and effective pharmacotherapeutic treat-
ments [1]. The mainstay in the pharmacotherapy of these envenomings, as well as of envenom-
ings by scorpions and spiders, is the timely administration of safe and effective antivenoms
[2,3]. Antivenoms are composed of immunoglobulins, or immunoglobulin fragments, purified
from the plasma of animals, usually horses, immunized with venoms. Currently, there is an
urgent need to improve antivenom availability, accessibility, and affordability on a global
basis, particularly for use in sub-Saharan Africa, Asia, and Latin America [1].
There is a long tradition in snake, scorpion, spider, and, more recently, caterpillar antiven-
oms production in Latin America, especially centered in public manufacturing laboratories in
Argentina, Brazil, Peru, Bolivia, Ecuador, Colombia, Venezuela, Costa Rica, and Mexico [4–6].
A network of public laboratories devoted to the production and quality control of antivenoms
was established in this region in the last decade [4,5], which has recently led to the creation of
the Latin American Network of Public Antivenom Manufacturing Laboratories (RELAPA,
Red Latinoamericana de Laboratorios Públicos Productores de Antivenenos) [6]. RELAPA aims
at consolidating governance mechanisms within a regional platform for technical cooperation,
technology transfer, research, and training for the regional improvement of antivenom avail-
ability, under the coordination of the Pan American Health Organization (PAHO) and its
office Centro Panamericano de Fiebre Aftosa (Panaftosa).
As part of the ongoing activities of RELAPA, a survey was sent by PAHO/Panaftosa to the
institutions integrating this network to assess the situation of antivenom manufacture in these
laboratories during the period January 2020 to July 2020, with the goal of analyzing in which
ways has antivenom production been affected in this extraordinary year, especially regarding
the impact of the Coronavirus Disease 2019AU : PleasenotethatCOVID   19hasbeendefinedasCoronavirusDisease2019initsfirstmentioninthesentenceAspartoftheongoingactivitiesofRELAPA; asurvey:::Pleasecorrectifnecessary:(COVID-19) pandemic, which has profoundly
stricken Latin America [7].
The survey was sent to the directors of the institutions of RELAPA (the list of institutions is
detailed in Fan and colleagues [6]). The survey included the following aspects: (a) What was
the demand and the production of antivenoms (including snake, scorpion, spider, and cater-
pillar antivenoms) during the period January 2020 to July 2020? (b) What was the effect of the
COVID-19 pandemic in (i) the number of professional and technical staff working to manu-
facture antivenom, (ii) acquisitions of consumables and laboratory equipment, (iii) overall
budget devoted to antivenom manufacture, and (iv) attention to the COVID-19 crisis in terms
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of development of therapeutic equine preparations against Severe Acute Respiratory Syn-
drome Coronavirus 2 (SARSAU : PleasenotethatSARS   CoV   2hasbeendefinedasSevereAcuteRespiratorySyndromeCoronavirus2initsfirstmentioninthesentenceThesurveywassenttothedirectorsoftheinstitutions:::Pleasecorrectifnecessary:-CoV-2), preparation of diagnostic reagents, quality control activ-
ities, or assignment of staff to attend other pandemic issues? (c) Which are the priorities of the
laboratories in the near future regarding regional cooperation in the field of antivenom manu-
facture and quality control? The survey was carried out between October 1 and October 19,
2020, using the platform Qualtrics (Qualtrics XM Platform, Seattle, Washington, United States
of America).
The responses to the survey are summarized as follows:
a. A total of 357,266 vials of antivenoms were produced by these laboratories in this period.
Seven laboratories manufactured antivenoms, whereas 5 laboratories did not. The reasons
for halting the production in these cases were the need to carry out improvements in infra-
structure for fulfilling the requirements of Good Manufacturing Practices (GMPs) in 4
cases and the restrictions to do face-to-face work in one institution. When compared to the
same period during 2019, the volume of production increased in 2 laboratories, remained
the same in 6 laboratories, and was reduced in 4 laboratories. An estimated average produc-
tion of antivenoms in these institutions during the past years (adjusted for 6 months) was
approximately 700,000 vials, based on the information provided by Fan and colleagues [6].
Hence, an overall reduction was observed for the region during the first half of 2020.
b. Regarding the national demand of antivenom by national public health institutions, as
compared to the same period in 2019, the demand increased for 3 laboratories, remained
stable for 7 laboratories, and decreased for 2 of them.
c. The laboratories attended various aspects related to the COVID-19 pandemics, as follows:
(i) production of therapeutic equine-derived antibodies against SARS-CoV-2 (6 laborato-
ries); (ii) production of diagnostic kits (2 laboratories); (iii) quality control activities (4 labo-
ratories); and (iv) transfer of staff to other departments to attend issues related to the
pandemics (7 laboratories). Two laboratories did not attend the COVID-19 emergency.
d. Regarding the impact of COVID-19 on the antivenom manufacturing activities, 10 labora-
tories reported a drop in the personnel dedicated to antivenoms, 7 laboratories had a reduc-
tion in the acquisition of consumables for antivenom production, and 4 laboratories
reported a reduction in the overall budget assigned to antivenom manufacture.
e. In terms of the priority needs of the laboratories for the near future, the following aspects
were identified in the survey: (i) implementation of a study on the preclinical efficacy of
antivenoms distributed in Latin America; (ii) training of technical and professional staff in
aspects related to antivenom production and quality control and implementation of GMPs;
(iii) improvements in immunization schemes and innovations in the use of adjuvants; (iv)
analysis of the situation of infrastructure and equipment in the laboratories; (v) pharmacov-
igilance of antivenoms; and (vi) translation to Spanish and Portuguese and distribution of
the WHO guidelines for antivenom production and quality control [2].
The main conclusion from this survey is that, despite the crisis generated in the region by
the COVID-19 pandemic, which has severely affected Latin America in terms of morbidity,
mortality, and socioeconomic impact, the universe of public antivenom manufacturing labora-
tories has sustained its activity, albeit at a reduced level as compared to historical records [6].
Six laboratories maintained the production of 2019 and 2 increased their output, while 4
reported to have decreased their production. The drop in the output of antivenoms, as com-
pared to the data provided by Fan and colleagues [6], was mostly because several laboratories
halted their production during the first half of 2020 for the reasons outlined above. Overall, the
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survey underscored the resilience of this regional collective of antivenom manufacturers in the
context of the COVID-19 crisis while, at the same time, highlights the need to complete the
improvements in various laboratories to resume the manufacture of antivenom once the infra-
structure works are finished. Whether the fiscal crisis generated in these countries by the pan-
demics will delay these projects is unknown at present.
It is noteworthy that the national demands of antivenoms by public health authorities (min-
istries of health and social security systems) in the countries where these manufacturers are
located was reduced only in 2 cases, as compared to the same period in 2019. This suggests
that public health authorities in the region have not neglected the relevance of snake bite
envenoming, even during this unprecedented health and fiscal crisis. Whether this trend will
continue is unknown, but it is expected that envenomings by animal bites and stings will
receive the required attention by regional and national health authorities in Latin America in
the coming years.
It is of interest that 10 out of 12 institutions where antivenoms are manufactured attended
in various ways the COVID-19 emergency. In particular, the regional efforts to generate
horse-derived immunoglobulin preparations anti-SARS-CoV-2 for the treatment of the coro-
navirus infections are remarkable and derive from the long-standing regional tradition in the
development and manufacture of antivenoms.
Finally, the survey identified a series or priority actions required to improve the landscape
of antivenom manufacture, control, and availability in the region. On the basis of this list of
priorities, activities are being planned for the year 2021, including (i) the preparation of a
research project to assess the preclinical efficacy of antivenoms, (ii) the translation of the
WHO guidelines of antivenoms, together with the organization of remote teaching modules
on the different aspects of these guidelines, to be offered to the laboratories of RELAPA, and
(iii) the implementation of a technical consultation virtual platform for exchanges of informa-
tion and expertise among RELAPA members in issues related to antivenom production. It is
expected that these actions will strengthen the regional capacity for antivenom manufacture
and control, with the consequent impact in the availability of this life-saving drug in Latin
America.
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